The content discusses how Grail Inc's telemedicine vendor erroneously sent letters to approximately 400 patients, suggesting they may have developed cancer. The company clarified that this error was not related to incorrect test results from their cancer detection blood test, Galleri. Patient health information was not compromised, and the software issue has been resolved. Additionally, Illumina Inc is facing regulatory challenges to divest Grail following its acquisition.
На другой язык
из исходного контента
www.medscape.com
Ключевые выводы из
by Clinical Rev... в www.medscape.com 06-02-2023
http://www.medscape.com/viewarticle/992718Дополнительные вопросы